Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

chronic lymphocytic leukemia

- PMLiVE

NICE backs GSK’s €594k gene therapy for rare disease

The treatment offers 'bubble baby' patients an alternative to a stem cell transplant

- PMLiVE

GSK gets another approval for Nucala in US

Its antibody is first approved treatment for a rare and sometimes life-threatening vascular disease

- PMLiVE

UK trumpets life sciences post-Brexit ‘sector deal’

Highlights commitments from GlaxoSmithKline, AstraZeneca and MSD

- PMLiVE

GSK’s ViiV gets US okay for two-drug HIV regimen

Juluca is a combination of ViiV’s Tivicay and Janssen’s Edurant

- PMLiVE

EMA approves GSK’s triple COPD therapy

Trelegy can now be marketed as a maintenance treatment in Europe

- PMLiVE

Ex-GSK head Witty to head group overseeing UK fast-track scheme

Medicines selected for the AAP could be made available much earlier

- PMLiVE

GSK to replace R&D head Vallance with Calico’s Hal Barron

Barron will also hold an executive director position on GSK’s board

- PMLiVE

GSK’s R&D head Vallance departs, possibly for government role

An independent panel of scientists proposed the UK role to Vallance, according to the FT

- PMLiVE

CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

US advisors recommend GSK's shingle vaccine be used instead of Merck's rival product

National Institute for Health and Care Excellence NICE logo

NICE backs GSK’s ‘bubble baby’ gene therapy

Strimvelis will treat children under the NHS for immunodeficiency

- PMLiVE

GSK’s shingles vaccine Shingrix claims US approval

Becomes first alternative to Merck & Co’s Zostavax

- PMLiVE

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Would follow in the footsteps of Novartis, Boehringer and Merck & Co if it does strike a deal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links